GlobeNewswire
-
Pasithea Therapeutics Presents Positive Initial Phase 1/1b Data for PAS-004, Showing Substantial Reductions in Cutaneous Neurofibroma Size and Early Activity in Plexiform Neurofibromas at the 2026 European Neurofibromatosis Conference
13/11/2026 -
Bavarian Nordic Launches Next Tranche of DKK 750 Million Share Buy-Back Program
13/11/2026 -
Bavarian Nordic Reports Strong Travel Health Growth in the Third Quarter and Confirms Solid Momentum for the Rest of the Year
13/11/2026 -
Henrik Juuel to Step Down as Chief Financial Officer of Bavarian Nordic in 2027
13/11/2026 -
HoneyPezil Announced New Advanced HoneyPezil Memory Capsules To Brain Health Support for Adults Seeking Everyday Cognitive Wellness in USA 2026.
13/11/2026 -
Reviva Reports Third Quarter 2026 Financial Results and Recent Business Highlights
13/11/2026 -
Cellectis Reports Third Quarter 2026 Financial Results and Provides a Business Update
13/11/2026 -
Cellectis publie ses résultats financiers du troisième trimestre 2026 et une mise à jour de ses activités
13/11/2026 -
Sienna Reports Third Quarter 2026 Financial Results and Continues Platform Growth
13/11/2026 -
LEQEMBI® Pen (Subcutaneous Formulation of LEQEMBI®) Now Available in Japan for Patients with Early Alzheimer’s Disease
13/11/2026 -
Windward Bio Announces Pricing of Initial Public Offering
13/11/2026 -
VitalHub Reports Third Quarter 2026 Results
12/11/2026 -
POTS Phase 2 Trial Shows Baloncibart, a First-in-Class NPR1 Blocking Antibody, Reduced Orthostatic Heart Rate and Improved Orthostatic Symptoms
12/11/2026 -
Longeveron Announces 2026 Third Quarter Financial Results and Provides Business Update
12/11/2026 -
Eledon Pharmaceuticals Reports Third Quarter 2026 Financial Results and Recent Business Highlights
12/11/2026 -
YD Bio Announces FDA Grant of INTERACT Meeting Request for YDB-LMSCEV-001, an Investigational Extracellular Vesicle Candidate for Dry Eye Disease
12/11/2026 -
Sutro Biopharma Reports Third Quarter 2026 Financial Results and Business Highlights
12/11/2026 -
Praxis Precision Medicines Details Launch Readiness for Relutrigine and Ulixacaltamide and Outlines Expanded Pipeline in Preparation to be the Preeminent CNS Biotech at Investor Day
12/11/2026 -
New Drug Application Submission Completed for Zipalertinib Plus Chemotherapy in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer
12/11/2026
Pages